HDAC inhibitors as a novel approach to modulate the cancer stein cell phenotype

被引：0
|
作者：
Shabason, J. [1 ]
Dowling, M. L. [1 ]
Maquilan, G. [1 ]
Malkowicz, S. B. [1 ]
Geiger, G. A. [1 ]
Kao, G. D. [1 ]
机构：
[1] Hosp Univ Penn, Philadelphia, PA 19104 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2008年 / 72卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2008.06.832
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S29 / S30
页数：2
相关论文
共 50 条
  • [31] Novel HDAC Inhibitors as Potential Anticancer Drugs
    Sanchez-Michael, Laura
    Quesada, Gabriela Torres
    Gutierrez, Denisse
    Varela-Ramirez, Armando
    Vijayalaxmi, S.
    Karki, Subhas
    Aguilera, Renato
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2024, 300 (03) : S210 - S210
  • [32] Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer
    Roy, Rubi
    Ria, Tasnim
    RoyMahaPatra, Debapriya
    Sk, Ugir Hossain
    ACS OMEGA, 2023, 8 (19): : 16532 - 16544
  • [33] Novel dual inhibitors of LSD1-HDAC6/8 for treatment of cancer
    Sivanandhan, Dhanalakshmi
    Rajagopal, Sridharan
    Nair, Sreekala
    Gajendran, Chandru
    Ghosh, Dimpy
    Nagaraj, P.
    Tantry, Subramanyam J.
    Dewang, Purushottam
    Hallur, Mahanandeesha S.
    Murugan, Kannan
    Srinatha, K. C.
    Kuntrapaku, Damodara
    Dilipkumar, M.
    Sharma, R.
    Meghashree, S.
    Kumar, Durga Prasanna
    Ingle, Suraj P.
    Zainuddin, Mohd
    Vinod, A. B.
    Rajagopal, Sriram
    CANCER RESEARCH, 2019, 79 (13)
  • [34] Design and development of a novel series of HDAC6-selective inhibitors for the treatment of cancer
    Shuttleworth, Stephen J.
    CANCER RESEARCH, 2014, 74 (19)
  • [35] Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines
    Sixto-Lopez, Yudibeth
    Antonio Gomez-Vidal, Jose
    de Pedro, Nuria
    Bello, Martiniano
    Cecilia Rosales-Hernandez, Martha
    Correa-Basurto, Jose
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [36] Novel dual inhibitors of LSD1-HDAC6/8 for treatment of cancer
    Dhanalakshmi, Sivanandhan
    Rajagopal, Sridharan
    Nair, Sreekala
    Gajendran, Chandru
    Ghosh, Dimpy
    Tantry, Subramanyam Janardhan
    Dewang, Purushottam
    Hallur, Mahanandeesha
    Kannan, M.
    Srinatha, K. C.
    Kuntrapaku, Damodara
    Dilipkumar, M.
    Sharma, Radha
    Meghashree, S.
    Kumar, D. P.
    Zainuddin, Mohd
    Vinod, A. B.
    Rajagopal, Sriram
    CANCER RESEARCH, 2018, 78 (13)
  • [37] Targeting breast cancer stem cells by novel HDAC3-selective inhibitors
    Hsieh, Hao-Yu
    Chuang, Hsiao-Ching
    Shen, Fang-Hsiu
    Detroja, Kinjal
    Hsin, Ling-Wei
    Chen, Ching-Shih
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 140 : 42 - 51
  • [38] Evaluation of Novel 3-Hydroxyflavone Analogues as HDAC Inhibitors against Colorectal Cancer
    Biswas, Subhankar
    Reddy, Neetinkumar D.
    Jayashree, B. S.
    Rao, C. Mallikarjuna
    ADVANCES IN PHARMACOLOGICAL SCIENCES, 2018, 2018
  • [39] Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines
    Yudibeth Sixto-López
    José Antonio Gómez-Vidal
    Nuria de Pedro
    Martiniano Bello
    Martha Cecilia Rosales-Hernández
    José Correa-Basurto
    Scientific Reports, 10
  • [40] Radiosensitization of cervical cancer cells by HDAC inhibitors
    Paydar, Ima
    Velena, Alfredo
    Grindrod, Scott
    Jung, Mira
    CANCER RESEARCH, 2017, 77
12345